Abstract
Persistent post-COVID syndrome, also referred to as long COVID, is a pathologic entity, which involves persistent physical, medical, and cognitive sequelae following COVID-19, including persistent immunosuppression as well as pulmonary, cardiac, and vascular fibrosis. Pathologic fibrosis of organs and vasculature leads to increased mortality and severely worsened quality of life. Current preclinical and clinical efforts are centered on the mechanisms and manifestations of COVID-19 and its presymptomatic and prodromal periods; by comparison, the postdrome, which occurs in the aftermath of COVID-19, which we refer to as persistent post-COVID-syndrome, has received little attention. Potential long-term effects from post-COVID syndrome will assume increasing importance. This review explores underlying mechanisms and possible manifestations of persistent post-COVID syndrome, and presents a framework of strategies for the diagnosis and management of patients with suspected or confirmed persistent post-COVID syndrome.
References
2. Levison M.E. Commentary: What we know so far about post-COVID Syndrome. Режим доступу: www.msdmanuals.com/professional/news/editorial/2020/09/23/20/17/post-covid-syndrome
3. Komaroff A. The tragedy of the post-COVID «long haulers». Режим доступу: health.harvard.edu/blog/the-tragedy-of-the-post-covid-longhaulers-
2020101521173
4. Carvalho-Schneider С. et al., Laurent E., Lemaignen A. Follow-up of adults with noncritical COVID-19 two months after symptom onset // Clin. Microbiol. Infect. — 2020 Oct 5. Doi: 10.1016 / j.cmi.2020.09.052 [Epub ahead of print].
5. Bansal M. Cardiovascular disease and COVID-19 // Diabetes Metab. Syndr. — 2020. — Vol. 14 (3). — P. 247-250.
6. Vaidya A., Dluhy R. Hyperaldosteronism. — 2020. [Updated 2016 Oct 19]. In: Feingold K.R., Anawalt B., Boyce A., et al., editors. Endotext [Internet].
South Dartmouth (MA): MDText.com, Inc. Режим доступу: https://www.ncbi.nlm.nih.gov/books/NBK279065/
7. Young B.E., Ong S.W.X., Kalimuddin S. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore // JAMA ([Internet]. (Available from:). — 2020. — P. 1-7.
8. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., Zhan S., Lu R., Li H., Tan W., Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV- 2) // Clin. Infect. Dis. — 2020.
9. Soubrier M., Pei J., Durand F., Gullestad L., John A. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis // Rheumatol Ther. — 2017. — Vol. 4 (1). — P. 133-149.
10. Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease [published online ahead of print, 2020 Mar 28] // Int. J. Cardiol. — 2020. S0167–5273(20)31593-X.
11. Biernacka A., Frangogiannis N.G. Aging and Cardiac Fibrosis // Aging Dis. — 2011. — Vol. 2 (2). — P. 158-173.
12. Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., Miao X., Li Y., Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China // JAMA Neurol. — 2020.
13. Fernández-Klett F., Priller J. The fibrotic scar in neurological disorders // Brain Pathol. — 2014. — Vol. 24 (4). — P. 404-13.
14. Wu Yeshun, Xu X., Chen Z., Duan J., Hashimoto K., Yang L., Liu C., Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain // Behav. Immun. — 2020. Режим доступу: https://doi.org/10.1016/j.bbi.2020.03.031
15. Milne G.J., Xie S. The effectiveness of social distancing in mitigating COVID-19 spread: a modelling analysis. — 2020. medRxiv. 03.20.20040055.